Ascendis Pharma A/S (ASND) News Today $125.82 -5.24 (-4.00%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 4.6% - Time to Sell?Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 4.6% - What's Next?January 22 at 1:20 PM | marketbeat.comResearch Analysts Offer Predictions for ASND FY2024 EarningsAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Leerink Partnrs lifted their FY2024 earnings estimates for Ascendis Pharma A/S in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will earn ($6.44) per share for the year, uJanuary 22 at 5:44 AM | marketbeat.comARS Investment Partners LLC Grows Position in Ascendis Pharma A/S (NASDAQ:ASND)ARS Investment Partners LLC increased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 265,480 shares of the biotechnology company's stJanuary 21 at 7:02 AM | marketbeat.comWedbush Cuts Earnings Estimates for Ascendis Pharma A/SJanuary 21 at 1:51 AM | americanbankingnews.comWedbush Lowers Earnings Estimates for Ascendis Pharma A/SAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Research analysts at Wedbush reduced their FY2027 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a report released on Thursday, January 16th. Wedbush analyst Y. Zhong now forecasts that the biotechnology company will postJanuary 20 at 1:53 AM | marketbeat.comShort Interest in Ascendis Pharma A/S (NASDAQ:ASND) Decreases By 5.5%Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 3,420,000 shares, a decline of 5.5% from the December 15th total of 3,620,000 shares. Based on an average daily trading volume, of 426,500 shares, the days-to-cover ratio is presently 8.0 days.January 18, 2025 | marketbeat.comJPMorgan Chase & Co. Has $5.95 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)JPMorgan Chase & Co. decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 93.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,834 shares of the biotechnology company's stock after selling 577,428 shares during theJanuary 17, 2025 | marketbeat.comPromising Growth Trajectory for Ascendis Pharma Driven by Yorvipath Launch and Pipeline AdvancementsJanuary 16, 2025 | markets.businessinsider.comAscendis Pharma A/S (NASDAQ:ASND) Stock Price Down 5.1% - Should You Sell?Ascendis Pharma A/S (NASDAQ:ASND) Shares Down 5.1% - Should You Sell?January 16, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of "Moderate Buy" by BrokeragesJanuary 14, 2025 | americanbankingnews.comAscendis Pharma’s Strategic Initiatives and Collaborations Drive Positive Growth Outlook and Buy RatingJanuary 13, 2025 | markets.businessinsider.comAscendis Pharma A/S (NASDAQ:ASND) Shares Up 5.9% - Should You Buy?Ascendis Pharma A/S (NASDAQ:ASND) Trading Up 5.9% - What's Next?January 13, 2025 | marketbeat.comAscendis Pharma stock falls on missed Skytrofa revenue forecastJanuary 13, 2025 | au.investing.comEvercore ISI Remains a Buy on Ascendis Pharma (ASND)January 13, 2025 | markets.businessinsider.comAscendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 12, 2025 | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of "Moderate Buy" by AnalystsAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and thirteen have issueJanuary 9, 2025 | marketbeat.comUBS Initiates Coverage of Ascendis Pharma A (ASND) with Buy RecommendationJanuary 8, 2025 | msn.comBank of America Securities Sticks to Their Buy Rating for Ascendis Pharma (ASND)January 7, 2025 | markets.businessinsider.comUBS Group Initiates Coverage on Ascendis Pharma A/S (NASDAQ:ASND)UBS Group assumed coverage on Ascendis Pharma A/S in a report on Tuesday. They set a "buy" rating and a $196.00 price objective for the company.January 7, 2025 | marketbeat.comAscendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comAscendis Pharma Updates Articles for Financial FlexibilityDecember 31, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM) and Ascendis Pharma (ASND)December 30, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Buy Rating on Ascendis Pharma (ASND)December 25, 2024 | markets.businessinsider.com7,376 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Acquired by Public Employees Retirement System of OhioPublic Employees Retirement System of Ohio purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,376 shares ofDecember 20, 2024 | marketbeat.comAscendis Pharma A/S Announces U.S. Commercial Availability of YORVIPATH® for Hypoparathyroidism TreatmentDecember 19, 2024 | quiverquant.comYORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in AdultsDecember 19, 2024 | finance.yahoo.comYORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in AdultsDecember 19, 2024 | globenewswire.comAscendis Pharma’s Promising Growth Prospects: Buy Rating Backed by Positive Clinical Results and Expected Share Price SurgeDecember 17, 2024 | markets.businessinsider.comAscendis Pharma (ASND) Gets a Buy from Stifel NicolausDecember 17, 2024 | markets.businessinsider.comAscendis Pharma: New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26December 16, 2024 | finanznachrichten.deAnalysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)December 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioLife Solutions (BLFS) and Delcath Systems (DCTH)December 16, 2024 | markets.businessinsider.comNew InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26December 16, 2024 | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Short Interest UpdateAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 3,770,000 shares, an increase of 5.6% from the November 15th total of 3,570,000 shares. Based on an average daily volume of 587,700 shares, the short-interest ratio is presently 6.4 days.December 16, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and twelDecember 15, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Nomura Asset Management Co. Ltd.Nomura Asset Management Co. Ltd. lifted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 42.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,000 shares oDecember 15, 2024 | marketbeat.comFDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon hGH for the Treatment of Adults with Growth Hormone DeficiencyDecember 14, 2024 | finanznachrichten.deAscendis Pharma A/S (NASDAQ:ASND) Stock Holdings Increased by Exome Asset Management LLCExome Asset Management LLC raised its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 119.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 43,849 shares of the biotechnology comDecember 14, 2024 | marketbeat.comY Intercept Hong Kong Ltd Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)Y Intercept Hong Kong Ltd bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,931 shares of the biotechnology company's stock, vDecember 13, 2024 | marketbeat.comAscendis Pharma announces FDA to review TransCon hGH sBLADecember 13, 2024 | markets.businessinsider.comAscendis Pharma’s TransCon hGH Receives FDA Review for Adult UseDecember 13, 2024 | markets.businessinsider.comAscensis Pharma Says FDA Will Review Application for Adult Treatment of Growth Hormone DeficiencyDecember 12, 2024 | marketwatch.comAscendis sBLA for Transcon hGH accepted by FDADecember 12, 2024 | msn.comFDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyDecember 12, 2024 | globenewswire.comEr-Kim and Ascendis’ endocrine therapy agreement extended in EurasiaDecember 11, 2024 | msn.comEr-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian MarketsDecember 10, 2024 | globenewswire.comFrazier Life Sciences Management L.P. Invests $19.91 Million in Ascendis Pharma A/S (NASDAQ:ASND)Frazier Life Sciences Management L.P. purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 133,333 shares of the biDecember 10, 2024 | marketbeat.comGroupama Asset Managment Acquires Shares of 404,000 Ascendis Pharma A/S (NASDAQ:ASND)Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 404,000 shares of the biotechnology comDecember 10, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Holdings Lowered by Wellington Management Group LLPWellington Management Group LLP trimmed its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 51.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,261,480 shares of the biotechnology company's stock after sDecember 9, 2024 | marketbeat.comXTX Topco Ltd Acquires Shares of 11,333 Ascendis Pharma A/S (NASDAQ:ASND)XTX Topco Ltd bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,333 shares of the biotechnology company's stocDecember 8, 2024 | marketbeat.com Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼0.540.64▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼136▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News Today TEVA News Today BGNE News Today SMMT News Today GMAB News Today VTRS News Today ITCI News Today MRNA News Today RDY News Today CTLT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTexas embraces new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
